Scinai Immunotherapeutics Ltd
SCNI
Company Profile
Business description
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units: (i) Scinai R&D, focused on the development of therapeutics in inflammation and immunology, and (ii) the contract development and manufacturing organization (CDMO) business. The CDMO business provides integrated development and manufacturing services to small and emerging biotech companies, supporting clients from early-stage development through clinical-stage production.
Contact
Hadassah Ein Kerem Campus
2nd Floor, Jerusalem BioPark
Jerusalem
ISRT: +972 89302529
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
45
Stocks News & Analysis
stocks
Chart of the Week: CGT reform strengthens the case for dividend investing
Why dividend stocks are gaining an edge after tax reform.
stocks
Finding ASX opportunities in lofty market conditions
A widening valuation gap is revealing more discounted ASX shares with moats.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,199.70 | 30.70 | 0.33% |
| CAC 40 | 8,408.27 | 50.51 | -0.60% |
| DAX 40 | 25,460.48 | 3.53 | -0.01% |
| Dow JONES (US) | 51,594.14 | 1,153.18 | -2.19% |
| FTSE 100 | 10,908.41 | 37.39 | 0.34% |
| HKSE | 25,807.92 | 497.07 | 1.96% |
| NASDAQ | 24,442.94 | 433.97 | -1.74% |
| Nikkei 225 | 61,258.34 | 175.85 | -0.29% |
| NZX 50 Index | 13,897.28 | 79.39 | -0.57% |
| S&P 500 | 7,316.15 | 112.63 | -1.52% |
| S&P/ASX 200 | 9,038.60 | 35.10 | 0.39% |
| SSE Composite Index | 3,828.47 | 15.15 | 0.40% |